Shares in narrow-moat ResMed remain undervalued following a solid fourth-quarter fiscal 2024. Underlying EBIT of USD 400 million was 2% higher than third-quarter fiscal 2024, with sales up 2% on ...
ResMed's fourth-quarter fiscal 2025 underlying EBIT grew 7% on the third, driven by increased product demand and gross margin expanding 150 basis points to 61% on component cost improvements and a ...
Zacks Investment Research on MSN
BSX vs. RMD: Which medical device stock is the stronger play now?
Boston Scientific BSX and Resmed RMD are two major players in the global medical devices market, with market capitalizations ...
Hello, and welcome to the Q4 Fiscal Year 2024 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. [Operator Instructions] Please note this conference call is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback